Eye Catching Active Stocks: Aurinia Pharmaceuticals (NASDAQ:AUPH), Alimera Sciences (NASDAQ:ALIM)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 24.00% to $10.54. Aurinia Pharmaceuticals Inc. (AUPH) dropped in extended session Monday after the Victoria, British Columbia-based biotech developer said it was launching a secondary offering of shares. Aurinia shares dropped 21% to $8.30 after hours. Aurinia did not specify the number of shares to be offered but said proceeds would be used for research and development activities including late-stage trials for lupus treatments. Aurinia currently has about 52.8 million shares outstanding. The share price of AUPH attracts active investors, as stock price of week volatility recorded 18.86%. The stock is going forward to its 52-week low with 506.44% and lagging behind from its 52-week high price with 21.99%.

Alimera Sciences, Inc. (NASDAQ:ALIM) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 12.77% to close at $1.59 with the total traded volume of 1.78 Million shares. Alimera Sciences, Inc. (ALIM), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, reported that Alimera Sciences Limited, its European subsidiary based in London, has signed an exclusive contract with Brill Pharma S. L. (Brill Pharma), Barcelona, Spain, for distribution of ILUVIEN in the Kingdom of Spain, Alimera’s sustained release intravitreal injection for the treatment of diabetic macular edema.

Under the terms of this contract, Brill Pharma will handle promotion, marketing and commercial activities in Spain for ILUVIEN. In addition, Brill will negotiate with the Spanish Ministry of Health on the appropriate confidential net price for reimbursement of ILUVIEN within the Spanish National Health System, as well as on the public price. The firm has institutional ownership of 80.60%, while insider ownership included 1.10%. Its price to sales ratio ended at 3.01. ALIM attains analyst recommendation of 2.00 with week’s performance of 18.66%.


About Aaron Smithies

Aaron Smithies has a wide look on current monetary and financial events. He is an editor and a writer. His views; At Streetwise Report, we think the best opportunities arise from a complete understanding of all investing disciplines in order to identify the most attractive stocks at any given time. Interests: Biotech, Finical markets, Dividend stock ideas & income, Energy stocks, Consumer goods stocks

Leave a Reply

Your email address will not be published. Required fields are marked *